Quarterly Result4 Nov 2025, 02:44 pm
Alembic Pharmaceuticals Reports Q2 FY26 Revenue Growth of 16% and PAT Growth of 20%
AI Summary
Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September 2025. The company's revenue from operations increased by 16% to Rs.1,910 Cr, EBITDA increased by 26% to Rs. 325 Cr, and Profit After Tax (PAT) reported at Rs.185 Cr, up by 20%. The India Branded Business delivered a 5% YoY growth, reaching 639 Cr in revenue for the quarter. The US Generics grew by 21% to Rs. 566 Cr. for the quarter, and the Ex-US International Generics grew by 31% to Rs. 392 Cr. The API business grew by 15% to Rs. 261 Cr. for the quarter.
Key Highlights
- Revenue from operations increased by 16% to Rs.1,910 Cr.
- EBITDA increased by 26% to Rs. 325 Cr.
- Profit After Tax (PAT) reported at Rs.185 Cr, up by 20%.
- India Branded Business delivered a 5% YoY growth, reaching 639 Cr in revenue for the quarter.
- US Generics grew by 21% to Rs. 566 Cr. for the quarter, and Ex-US International Generics grew by 31% to Rs. 392 Cr.
- API business grew by 15% to Rs. 261 Cr. for the quarter.